SCHEMBL30765647

SCHEMBL30765647

O=C(Cn1c(-c2ccc(OC3CS(=O)(=O)C3)cc2)ncc(NCCCc2ccccc2)c1=O)NCc1cc2cnccc2[nH]1

nearest known ligand 0.37

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
F2 P00734 10/20 0.37
AVPR1B P47901 2/20 0.35
PRSS1 P07477 3/20 0.35
F7 P08709 1/20 0.35
F3 P13726 1/20 0.35
PRSS2 P07478 1/20 0.35
PRSS3 P35030 1/20 0.35
ELANE P08246 2/20 0.34
CASP1 P29466 1/20 0.34
CMA1 P23946 1/20 0.34
CTRC Q99895 1/20 0.34
KDM6B O15054 1/20 0.34
KDM4C Q9H3R0 1/20 0.34
NTRK1 P04629 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765570 0.97 AVPR1B (0.37) F2AVPR1BPRSS1F7F3
SCHEMBL30765716 0.92 F2 (0.37) F2AVPR1BPRSS1PRSS2PRSS3
SCHEMBL30765470 0.89 AVPR1B (0.37) F2AVPR1BPRSS1F7F3
SCHEMBL30765562 0.87 F2 (0.36) F2AVPR1BPRSS1PRSS2PRSS3
SCHEMBL30765912 0.87 PRKAG1 (0.36) F2AVPR1BPRSS1PRSS2PRSS3
SCHEMBL30765437 0.86 HDAC6 (0.41) F2PRSS1F7F3ELANE
SCHEMBL30765474 0.86 F2 (0.38) F2PRSS1F7F3PRSS2
SCHEMBL30765550 0.86 F2 (0.38) F2AVPR1BPRSS1F7F3
SCHEMBL30765489 0.85 F2 (0.39) F2AVPR1BPRSS1F7F3
SCHEMBL30765583 0.84 F2 (0.40) F2PRSS1F7F3PRSS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed